207 related articles for article (PubMed ID: 23507428)
1. Mechanisms of resistance to anti-angiogenesis therapies.
Giuliano S; Pagès G
Biochimie; 2013 Jun; 95(6):1110-9. PubMed ID: 23507428
[TBL] [Abstract][Full Text] [Related]
2. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
3. Biological mechanisms of bevacizumab-associated adverse events.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
[TBL] [Abstract][Full Text] [Related]
4. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
Crawford Y; Ferrara N
Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
[TBL] [Abstract][Full Text] [Related]
5. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Tonra JR; Hicklin DJ
Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of apelin as a therapeutic target in cancer: a patent review.
Rayalam S; Della-Fera MA; Kasser T; Warren W; Baile CA
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):367-72. PubMed ID: 21612576
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
Shojaei F
Cancer Lett; 2012 Jul; 320(2):130-7. PubMed ID: 22425960
[TBL] [Abstract][Full Text] [Related]
11. Response to anti-angiogenesis: an ever changing feature.
Bertolini F
Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
[TBL] [Abstract][Full Text] [Related]
12. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Itatani Y; Kawada K; Yamamoto T; Sakai Y
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to vascular endothelial growth factor blockade.
Abdullah SE; Perez-Soler R
Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks].
Wagner AD; Zaman K; Peters S; Montemurro M; Leyvraz S
Rev Med Suisse; 2010 May; 6(250):1070-3. PubMed ID: 20564866
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
Takano S
Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
[TBL] [Abstract][Full Text] [Related]
17. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
19. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
